Get started
Author

Géraldine Teppaz

Observed names: G. Teppaz, Geraldine Teppaz, Geraldine teppaz, Teppaz Geraldine, Teppaz, Géraldine
Observed institutions: Centre National de la Recherche Scientifique, Inserm, Université de Montpellier, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, OSE Immunotherapeutics (France), Institut de Génomique Fonctionnelle, Université de Nantes, University of Toledo, Nantes Université
ORCID: 0000-0002-5835-2493
Observed ORCID: 0000-0002-5835-2493
OpenAlex ID: A5087659024
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance
2020 · Vanessa Gauttier, Sabrina Pengam, et al. · Journal of Clinical Investigation · 84
PDF
Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution
2021 · C. Trilleaud, V. Gauttier, et al. · Science Advances · 75
Tumor targeting of the IL‐15 superagonist RLI by an anti‐GD2 antibody strongly enhances its antitumor potency
2013 · Marie Vincent, Anne Bessard, et al. · International Journal of Cancer · 70
PDF
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists
2016 · Mélanie Desbois, Pauline Le Vu, et al. · The Journal of Immunology · 65
Toward Efficient Drug Screening by Homogeneous Assays Based on the Development of New Fluorescent Vasopressin and Oxytocin Receptor Ligands
2007 · Laura Albizu, Géraldine Teppaz, et al. · Journal of Medicinal Chemistry · 64
SIRPα/CD47 axis controls the maintenance of transplant tolerance sustained by myeloid-derived suppressor cells
2019 · Sabrina Pengam, Justine Durand, et al. · American Journal of Transplantation · 44
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse
2014 · Marie Vincent, Géraldine Teppaz, et al. · mAbs · 38
PDF
CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy
2022 · Marion Drouin, Javier Saenz, et al. · Science Advances · 25
PDF
Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine
2020 · V. Gauttier, A. Morello, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 18
PDF
First-in-Human Study in Healthy Subjects with the Noncytotoxic Monoclonal Antibody OSE-127, a Strict Antagonist of IL-7Rα
2023 · Nicolas Poirier, Irène Baccelli, et al. · The Journal of Immunology · 13
Abstract 910: A novel bifunctional anti-PD-1 IL-7 fusion protein to reinvigorate exhausted T cell and disarms Treg suppressive activity
2020 · Aurore Morello, Justine Durand, et al. · Cancer Research · 3
1370 Anti-PD-1/IL-7v immunocytokine favors proliferation & survival of TCF1+ stem like memory T cells and a durable in vivo efficacy in monotherapy or using combinatorial strategy
2023 · Aurore Morello, Justine Durand, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 1766: Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis
2021 · Vanessa Gauttier, Margot Lavy, et al. · Cancer Research · 2
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours
2026 · Marie Robert, Nuria Kotecki, et al. · European Journal of Cancer · 1
1366 Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and long-lasting in vivo efficacy
2022 · Aurore Morello, Margaux Seite, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
794 Long-term anti-tumor preclinical efficacy of an optimized anti PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity
2021 · Aurore morello, Margaux Seite, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Abstract 3259: CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy controlling damaged and tumor cells phagocytosis
2020 · Vanessa Gauttier, Marion Drouin, et al. · Cancer Research · 1
Novel agonist monoclonal antibody targeting GPCR to decrease neutrophil accumulation and initiate resolution of chronic inflammation 2310040
2026 · Charles-Antoine Coupet, Charlène Trilleaud, et al. · The Journal of Immunology
1190 OSE-cytomask®, a novel CIS-demasking cytokine technology to increase therapeutic index of immunocytokine
2025 · Margaux Seite, Caroline Mary, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 3412: Cis demasking cytokine technology improves therapeutic index of immunocytokine
2025 · Caroline Mary, Margaux Seite, et al. · Cancer Research
Abstract 7293: First in class Anti-CLEC-1A myeloid checkpoint antibodies for the treatment of solid tumors with monotherapy and combination therapy efficacies
2025 · Etienne Foucher, Mylène Deramé, et al. · Cancer Research
Abstract 6342: Anti-tumor in vivo efficacy of different classes of anti-CLEC-1 myeloid checkpoint antibodies in monotherapy and in combination with chemotherapeutic agents
2024 · Aurore Morello, Mylène Deramé, et al. · Cancer Research
Abstract 4070: CIS-demasking cytokine linker technology allows a selective cytokine delivery to activated immune cells while sparing others and peripheral toxicity
2024 · Aurore Morello, Caroline Mary, et al. · Cancer Research
852 Modified-epitope-based vaccine (OSE2101) combined with anti-PD-1/IL-7v bispecific antibody sustains long-lasting tumor specific antigen memory T cell response in vivo
2023 · Belarif Lyssia, Julien Taurelle, et al. · Journal for ImmunoTherapy of Cancer
PDF
493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoralin vivoefficacies in humanized preclinical models
2023 · Irène Baccelli, Caroline Mary, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 40
Citation count: 507
H-index: 10
I10-index: 10
Year
Topic
Type